Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Radiation Oncology
Published in: Journal of Radiation Oncology 1/2012

01-03-2012 | Review

Stereotactic body radiotherapy for prostate cancer: ready for prime time?

Author: Alan Katz

Published in: Journal of Radiation Oncology | Issue 1/2012

Login to get access

Abstract

Stereotactic body radiotherapy (SBRT) delivers a few high doses of radiation to a target in the body with extreme accuracy and conformality. Prostate cancer’s great sensitivity to dose per fraction allows SBRT’s hypofractionated delivery the opportunity to increase the biological equivalent dose delivered to the prostate while relatively decreasing the dose to the normal bladder and rectal tissues. In recent years, clinical outcomes supporting the safety and increasingly longer-term efficacy of SBRT have been published. This review examines the basis of hypofractionation, current SBRT delivery mechanisms, and the growing body of clinical outcomes of SBRT for prostate cancer. In addition, given the increased interest in SBRT for prostate cancer, clinical issues in the treatment of prostate cancer with SBRT and a look into the future of SBRT for prostate cancer are examined.
Literature
1.
Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13PubMedCrossRef
2.
Fowler JF (2005) The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44:265–276PubMedCrossRef
3.
Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-Fractionation Sensitivity of Prostate Cancer Deduced from Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):17–24CrossRef
4.
Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60:1013–1015PubMedCrossRef
5.
Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021–1031PubMedCrossRef
6.
Shaffer R, Pickles T, Lee R et al (2011) Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure. Int J Radiat Oncol Biol Phys 79:1029–1036PubMedCrossRef
7.
Boike TP, Lotan Y, Cho LC et al (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020–2026PubMedCrossRef
8.
King CR, Brooks JD, Gill H et al (2009) Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II Clinical Trial. Int J Radiat Oncol Biol Phys 73:1043–1048PubMedCrossRef
9.
King CR, Brooks JD, Gill H et al Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011
10.
Katz AJ, Santoro M, Ashley R et al Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010;10:1
11.
Mantz C, Fernandez E, Zucker I et al (2011) A phase II trial of real-time target tracking SBRT for low-risk prostate cancer utilizing the calypso 4D localization system: patient-reported quality of life and toxicity outcomes. Int J Radiat Oncol Biol Phys 81:S100CrossRef
12.
Freeman DE, Friedland JL, Masterson-McGary ME (2010) Stereotactic radiosurgery for low-intermediate risk prostate cancer: an emerging treatment approach. J Clin Oncol 33:208
13.
McBride SM, Wong DS, Dombrowski JJ et al Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2011
14.
Lukka HR. A randomized phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer-RTOG CCOP Study; 2011.RTOG Website
15.
Kupelian PA, Willoughby TR, Reddy CA et al (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys 68:1424–1430PubMedCrossRef
16.
Rene N, Faria S, Cury F et al (2010) Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys 77:805–810PubMedCrossRef
17.
Arcangeli G, Saracino B, Gomellini S et al (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78:11–18PubMedCrossRef
18.
Pollack A, Walker G, Buyyounouski M et al (2011) Five Year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 81:S1CrossRef
19.
Ritter MA, Forman JD, Kupelian PA et al (2011) Five-year efficacy and toxicity outcomes from a phase i/ii trial of increasingly hypofractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 81:S99CrossRef
20.
Kupelian PA, Thakkar VV, Khuntia D et al (2005) Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 63:1463–1468PubMedCrossRef
21.
Zelefsky MJ, Chan H, Hunt M et al (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419PubMedCrossRef
22.
Collins CD, Lloyd-Davies RW, Swan AV (1991) Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 3:127–132CrossRef
23.
Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61:1306–1316PubMedCrossRef
24.
Martinez AA, Demanes J, Vargas C (2010) High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33:481–488PubMedCrossRef
25.
Demanes DJ, Martinez AA, Ghilezan M (2011) High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 81:1286–1292PubMedCrossRef
26.
Yoshioka Y, Konishi K, Sumida I et al (2011) Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 80:469–475PubMedCrossRef
27.
Fuller DB, Naitoh J, Lee C et al (2008) Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70:1588–1597PubMedCrossRef
28.
Balter JM, Sandler HM, Lam K et al (1995) Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys 31:113–118PubMedCrossRef
29.
Kron T, Thomas J, Fox C et al (2010) Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-treatment imaging of patients with implanted fiducial markers. Radiother Oncol 95:191–197PubMedCrossRef
30.
King CR, Lehmann J, Adler JR et al (2003) CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2:25–30PubMed
31.
Hossain S, Xia P, Chuang C et al (2008) Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys 35:4041–4048PubMedCrossRef
32.
Dawood O, Sims S, Dooley J et al (2009) Impact of robotic IMRT on normal tissue sparing in the treatment of prostate cancer as compared to conventional IMRT. J Urol 183:674–675CrossRef
33.
Xie Y, Djajaputra D, King CR et al (2008) Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 72:236–246PubMedCrossRef
34.
Lei S, Piel N, Oermann E et al (2010) Six-dimensional correction of intra-fractional prostate motion with CyberKnife stereotactic body radiation therapy. Front Radiat Oncol 1:48
35.
Fuller DB, Naitoh J, Reilly M et al (2009) Virtual HDR prostate cyberknife radiosurgery: efficacy, toxicity and quality of life. 2009 CyberKnife Users’ Meeting, Hollywood
36.
Madsen BL, Hsi RA, Pham HT et al (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67:1099–1105PubMedCrossRef
37.
Tang CI, Loblaw DA, Cheung P et al (2008) Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol) 20:729–737CrossRef
38.
Choi C, Cho G, Kim K et al (2007) Stereotactic radiation therapy of localized prostate cancer using CyberKnife. Int J Radiat Oncol Biol Phys 69:S375CrossRef
39.
Kang JK, Cho CK, Choi CW et al (2011) Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 97:43–48PubMed
40.
Friedland JL, Freeman DE, Masterson-McGary ME et al (2009) Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 8:387–392PubMed
41.
Katz AJ, Santoro M, DiBlasio F et al (2011) Stereotactic body radiation therapy for low, intermediate, and high-risk prostate cancer: disease control and quality of life. Int J Radiat Oncol Biol Phys 81:S100CrossRef
42.
Freeman DE, King CR (2011) Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 6:3PubMedCrossRef
43.
Jabbari S, Weinberg VK, Kaprealian T et al Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and psa response. Int J Radiat Oncol Biol Phys 2012
44.
Fuller DB, Shirazi R, Naitoh J et al (2011) Virtual HDR SBRT For Localized prostatic carcinoma: efficacy and quality of life assessment. Int J Radiat Oncol Biol Phys 81:S423–S424CrossRef
45.
Bolzicco G, Favretto MS, Scremin E et al (2010) Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 9:473–477PubMed
46.
Aluwini S, van Rooij P, Hoogeman M et al (2010) CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol 24:865–869PubMedCrossRef
47.
Townsend NC, Huth BJ, Ding W et al (2011) Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 34:6–10PubMedCrossRef
48.
Jabbari S, Weinberg VK, Shinohara K et al (2010) Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 76:36–42PubMedCrossRef
49.
Ray ME, Thames HD, Levy LB et al (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64:1140–1150PubMedCrossRef
50.
Zelefsky MJ, Kuban DA, Levy LB et al (2007) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327–333PubMedCrossRef
51.
Stock RG, Klein TJ, Cesaretti JA et al (2009) Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 74:753–758PubMedCrossRef
52.
Meier R 2008 CyberKnife Radiosurgery for organ-confined prostate cancer: homogenous dose distribution.
53.
Fuller DB 2008CyberKnife radiosurgery for low & intermediate risk prostate cancer: emulating HDR brachytherapy dosimetry
54.
Fuller DB, Mardirossian G, Wong D et al (2010) Prospective Evaluation of stereotactic radiotherapy for low and intermediate risk prostate cancer: emulating HDR brachytherapy dose distribution. Int J Radiat Oncol Biol Phys 78:S358–S359CrossRef
55.
Meier R, Beckman A, Kaplan I et al (2010) Stereotactic radiotherapy for organ-confined prostate cancer: early toxicity and quality of life outcomes from a multi-institutional trial. Int J Radiat Oncol Biol Phys 78:S57CrossRef
56.
Partin AW, Yoo J, Carter HB et al (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110–114PubMed
57.
Galalae RM, Kovacs G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90PubMedCrossRef
58.
Katz A, Santoro M, Ashley R et al (2010) Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 9:575–582PubMed
59.
Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261PubMedCrossRef
60.
Lawton CA, DeSilvio M, Lee WR et al (2007) Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys 67:39–47PubMedCrossRef
61.
Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366–5373PubMedCrossRef
62.
Kupelian P, Willoughby T, Mahadevan A et al (2007) Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 67:1088–1098PubMedCrossRef
63.
Cahlon O, Zelefsky MJ, Shippy A et al (2008) Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71:330–337PubMedCrossRef
64.
Nguyen PL, D’Amico AV (2008) Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 26:2055–2056, author reply 2056–2057PubMedCrossRef
65.
Beyer DC (2004) Salvage brachytherapy after external-beam irradiation for prostate cancer. Oncology (Williston Park) 18:151–158, discussion 158–160, 163–154
66.
Grado GL, Collins JM, Kriegshauser JS et al (1999) Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53:2–10PubMedCrossRef
67.
Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67:1106–1112PubMedCrossRef
68.
Jereczek-Fossa BA, Beltramo G, Fariselli L et al Robotic Image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2011
69.
Fuller DB, Virtual HDR (2011) CyberKnife treatment for localized prostatic carcionoma: principles and clinical update. In: Ponsky LE (ed) Treating prostate cancer and related genitourinary applications. Springer, Berline, pp 155–163
70.
Simone NL, Menard C, Soule BP et al (2008) Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by EPIC score. Int J Radiat Oncol Biol Phys 70:90–95PubMedCrossRef
71.
Teh BS, McGary JE, Dong L et al (2002) The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: more than just a prostate gland immobilization device? Cancer J 8:476–483PubMedCrossRef
72.
Sanghani MV, Ching J, Schultz D et al (2004) Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy. Urol Oncol 22:165–168PubMedCrossRef
73.
van Lin EN, Hoffmann AL, van Kollenburg P et al (2005) Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy. Int J Radiat Oncol Biol Phys 63:565–576PubMedCrossRef
74.
King CR, Lo A, Kapp DS (2009) Testicular dose from prostate cyberknife: a cautionary note. Int J Radiat Oncol Biol Phys 73:636–637, author reply 637PubMedCrossRef
75.
Fuller DB (2009) Testicular dose from prostate cyberknife: a cautionary note in regard to King et al. Int J Radiat Oncol Biol Phys 73:637PubMed
76.
Oermann EK, Suy S, Hanscom HN et al (2011) Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol 4:12PubMedCrossRef
77.
Yogeswaren S, Teh B, Mai W et al (2004) Radiation dose to testicles and serum testosterone levels in low risk prostate cancer patients undergoing intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys 60:S456CrossRef
78.
Wiegner EA, King CR (2010) Sexual Function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 78:442–448PubMedCrossRef
79.
Sannazzari GL, Ragona R, Ruo Redda MG et al (2002) CT-MRI image fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer. Br J Radiol 75:603–607PubMed
80.
Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073PubMedCrossRef
81.
D’Amico AV, Chen MH, Renshaw AA et al (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299:289–295PubMedCrossRef
82.
Katz AJ, Santoro M, Ashley R et al (2011) Stereotactic body radiation therapy for low- and low-intermediate-risk prostate cancer: is there a dose effect? Front Radiat Oncol 1:49
83.
Low RN, Fuller DB, Muradyan N (2011) Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: assessment of response to hypofractionated robotic stereotactic body radiation therapy. AJR Am J Roentgenol 197:907–915PubMedCrossRef
84.
Sauvain JL, Palascak P, Bourscheid D et al (2003) Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. Eur Urol 44:21–30, discussion 30–21PubMedCrossRef
85.
Bea`umont launches study of single-dose radiation treatment for prostate cancer; 2011
Metadata
Title
Stereotactic body radiotherapy for prostate cancer: ready for prime time?
Author
Alan Katz
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Journal of Radiation Oncology / Issue 1/2012
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-012-0011-5

Other articles of this Issue 1/2012

Journal of Radiation Oncology 1/2012 Go to the issue

Original Research

National survey of healthcare providers’ views on the risk of inadvertent exposure of pregnant patients to ionizing radiation in Canadian radiotherapy departments

Original Research

Experience using frameless fractionated radiosurgery for the treatment of orbital and ocular tumors

Review

Diagnosis and treatment options including stereotactic body radiation therapy (SBRT) for adrenal metastases

Review

Stereotactic body radiation therapy in head and neck, gynecologic, and pediatric malignancies

Case Report

Hyperfractionated craniospinal re-irradiation for recurrent/progressive disseminated medulloblastoma using image-guided radiotherapy: leveraging radiobiology with technology

Editorial

From the editorial board
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits